---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005150"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:08:15.545853+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech reports record FY2022 revenue $75.7M, net loss $(86.6)M; BLA accepted for cosibelimab

## Summary
- Record consolidated net revenue of $75.7M for FY2022, up from $68.8M in FY2021; $71.0M from dermatology products.
- GAAP net loss attributable to common stockholders of $(86.6)M ($(0.97)/share) vs $(64.7)M ($(0.79)/share) in FY2021.
- Cash, equivalents and restricted cash $181.0M at Dec 31, 2022, down from $308.0M at Dec 31, 2021.
- FDA accepted BLA for cosibelimab (anti-PD-L1) for cSCC; PDUFA goal date Jan 3, 2024; no advisory committee planned.
- Expects to complete rolling NDA for CUTX-101 (Menkes disease) and submit NDA for DFD-29 (rosacea) in 2023.

## SEC filing metadata
- accession: 0001558370-23-005150
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/0001558370-23-005150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/fbio-20230330x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005150
- JSON: https://secwatch.observer/filing/0001558370-23-005150.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005150.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported full-year ended December 31, 2022 results: revenue $75.7 million.
  - Period: full-year ended December 31, 2022
  - Revenue: $75.7 million
  - Result: reported results
  source text: We also generated record consolidated net revenues of $75.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/0001558370-23-005150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.